REBLOZYL® (luspatercept-aamt) is a prescription medicine used to treat anemia (low red blood cells) in adults with myelodysplastic syndromes with ring sideroblasts (MDS-RS) or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) who need regular RBC transfusions and have not responded well to or cannot receive an erythropoiesis stimulating agent (ESA).
REBLOZYL is not for use as a substitute for RBC transfusions in people who need immediate treatment for anemia.
It is not known if REBLOZYL is safe or effective in children under 18 years of age.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
Starting a medicine is a lot to take in. Knowing how REBLOZYL has impacted other people can help you understand what to expect from treatment.
The main goal of the study was to stop the need for red blood cell (RBC) transfusions for at least 8 weeks during the first 24 weeks of treatment.
People in both treatment groups were allowed to receive best supportive care. This included RBC transfusions, as needed.
REBLOZYL helped patients lower their need for RBC transfusions
Percentage of people who had
no rbc transfusions for at least 8 weeks
during the first 24 weeks of treatment
Patients could not be a part of the study if they had:
It’s important to know about the possible side effects of REBLOZYL before beginning treatment. Remember: people may react to medicines differently, and that’s expected.
The possible side effects of REBLOZYL are well-known. Be sure to talk with your healthcare team about what to expect when starting treatment with REBLOZYL.